🚀 VC round data is live in beta, check it out!
Emergent BioSolutions Valuation Multiples
Discover revenue and EBITDA valuation multiples for Emergent BioSolutions and similar public comparables like Eton Pharmaceuticals, Newron Pharmaceuticals, Regenxbio, Invivyd and more.
Emergent BioSolutions Overview
About Emergent BioSolutions
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
Founded
1998
HQ
Employees
900
Website
Financials (LTM)
EV
$890M
Emergent BioSolutions Financials
Emergent BioSolutions reported last 12-month revenue of $743M and EBITDA of $194M.
In the same LTM period, Emergent BioSolutions generated $404M in gross profit, $194M in EBITDA, and $74M in net income.
Revenue (LTM)
Emergent BioSolutions P&L
In the most recent fiscal year, Emergent BioSolutions reported revenue of $743M and EBITDA of $238M.
Emergent BioSolutions expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $743M | XXX | $743M | XXX | XXX | XXX |
| Gross Profit | $404M | XXX | $379M | XXX | XXX | XXX |
| Gross Margin | 54% | XXX | 51% | XXX | XXX | XXX |
| EBITDA | $194M | XXX | $238M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 32% | XXX | XXX | XXX |
| EBIT Margin | 12% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $74M | XXX | $87M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | — | — | $367M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Emergent BioSolutions Stock Performance
Emergent BioSolutions has current market cap of $472M, and enterprise value of $890M.
Market Cap Evolution
Emergent BioSolutions' stock price is $8.99.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $890M | $472M | 0.0% | XXX | XXX | XXX | $1.65 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEmergent BioSolutions Valuation Multiples
Emergent BioSolutions trades at 1.2x EV/Revenue multiple, and 4.6x EV/EBITDA.
EV / Revenue (LTM)
Emergent BioSolutions Financial Valuation Multiples
As of March 21, 2026, Emergent BioSolutions has market cap of $472M and EV of $890M.
Equity research analysts estimate Emergent BioSolutions' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Emergent BioSolutions has a P/E ratio of 6.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $472M | XXX | $472M | XXX | XXX | XXX |
| EV (current) | $890M | XXX | $890M | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | 1.2x | XXX | XXX | XXX |
| EV/EBITDA | 4.6x | XXX | 3.7x | XXX | XXX | XXX |
| EV/EBIT | 10.1x | XXX | 7.9x | XXX | XXX | XXX |
| EV/Gross Profit | 2.2x | XXX | 2.3x | XXX | XXX | XXX |
| P/E | 6.4x | XXX | 5.4x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 5.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Emergent BioSolutions Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Emergent BioSolutions Margins & Growth Rates
Emergent BioSolutions' revenue in the last 12 month grew by 5%.
Emergent BioSolutions' revenue per employee in the last FY averaged $0.8M.
Emergent BioSolutions' rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Emergent BioSolutions' rule of X is 37% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Emergent BioSolutions Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 0% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Growth | (21%) | XXX | (36%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 37% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 36% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Emergent BioSolutions Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Eton Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Newron Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Regenxbio | XXX | XXX | XXX | XXX | XXX | XXX |
| Invivyd | XXX | XXX | XXX | XXX | XXX | XXX |
| Blau Farmacêutica | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Emergent BioSolutions M&A Activity
Emergent BioSolutions acquired XXX companies to date.
Last acquisition by Emergent BioSolutions was on XXXXXXXX, XXXXX. Emergent BioSolutions acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Emergent BioSolutions
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEmergent BioSolutions Investment Activity
Emergent BioSolutions invested in XXX companies to date.
Emergent BioSolutions made its latest investment on XXXXXXXX, XXXXX. Emergent BioSolutions invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Emergent BioSolutions
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Emergent BioSolutions
| When was Emergent BioSolutions founded? | Emergent BioSolutions was founded in 1998. |
| Where is Emergent BioSolutions headquartered? | Emergent BioSolutions is headquartered in United States. |
| How many employees does Emergent BioSolutions have? | As of today, Emergent BioSolutions has over 900 employees. |
| Who is the CEO of Emergent BioSolutions? | Emergent BioSolutions' CEO is Joseph C. Papa. |
| Is Emergent BioSolutions publicly listed? | Yes, Emergent BioSolutions is a public company listed on NYSE. |
| What is the stock symbol of Emergent BioSolutions? | Emergent BioSolutions trades under EBS ticker. |
| When did Emergent BioSolutions go public? | Emergent BioSolutions went public in 2006. |
| Who are competitors of Emergent BioSolutions? | Emergent BioSolutions main competitors are Eton Pharmaceuticals, Newron Pharmaceuticals, Regenxbio, Invivyd. |
| What is the current market cap of Emergent BioSolutions? | Emergent BioSolutions' current market cap is $472M. |
| What is the current revenue of Emergent BioSolutions? | Emergent BioSolutions' last 12 months revenue is $743M. |
| What is the current revenue growth of Emergent BioSolutions? | Emergent BioSolutions revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Emergent BioSolutions? | Current revenue multiple of Emergent BioSolutions is 1.2x. |
| Is Emergent BioSolutions profitable? | Yes, Emergent BioSolutions is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Emergent BioSolutions? | Emergent BioSolutions' last 12 months EBITDA is $194M. |
| What is Emergent BioSolutions' EBITDA margin? | Emergent BioSolutions' last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Emergent BioSolutions? | Current EBITDA multiple of Emergent BioSolutions is 4.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.